Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Free Report) was the recipient of a significant decline in short interest during the month of September. As of September 30th, there was short interest totalling 15,900 shares, a decline of 14.5% from the September 15th total of 18,600 shares. Based on an average daily volume of 8,600 shares, […]
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Free Report) saw a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 33,600 shares, a growth of 20.0% from the June 30th total of 28,000 shares. Approximately 1.6% of the shares of the company are short sold. Based […]
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Rating) shares traded down 0.9% during mid-day trading on Wednesday . The stock traded as low as $4.25 and last traded at $4.31. 22,759 shares were traded during trading, a decline of 5% from the average session volume of 23,926 shares. The stock had previously closed at $4.35. Cyclerion […]
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Rating)’s share price dropped 7.4% on Tuesday . The stock traded as low as $0.23 and last traded at $0.26. Approximately 210,457 shares were traded during mid-day trading, a decline of 13% from the average daily volume of 243,103 shares. The stock had previously closed at $0.28. Cyclerion Therapeutics […]
Recent positive MELAS clinical study data drive urgency to deliver potential first-ever therapy for patients with rare, genetic mitochondrial diseases .